About OMass Therapeutics
OMass Therapeutics is a company based in Oxford (United Kingdom) founded in 2016 by Carol Robinson.. OMass Therapeutics has raised $166.24 million across 4 funding rounds from investors including Syncona, University of Oxford and Oxford University Innovation. The company has 36 employees as of September 30, 2021. OMass Therapeutics offers products and services including Biochemistry Services and Mass Spectrometry Solutions. OMass Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Aclaris Therapeutics, Neurocrine and ADMA Biologics, among others.
- Headquarter Oxford, United Kingdom
- Employees 36 as on 30 Sep, 2021
- Founders Carol Robinson
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Omass Therapeutics Limited
- Date of Incorporation 26 Feb, 2016
- Jurisdiction OXFORD, ENGLAND
-
Annual Revenue
$54.27 K (USD)-83as on Dec 31, 2019
-
Net Profit
$-12.52 M (USD)-47as on Dec 31, 2021
-
EBITDA
-
Total Equity Funding
$166.24 M (USD)
in 4 rounds
-
Latest Funding Round
$12.45 M (USD), Series B
May 15, 2023
-
Investors
Syncona
& 7 more
-
Employee Count
36
as on Sep 30, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of OMass Therapeutics
OMass Therapeutics offers a comprehensive portfolio of products and services, including Biochemistry Services and Mass Spectrometry Solutions. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Provides tools for analyzing target interactions in ecosystems
Offers custom chemistry for drug discovery applications
Unlock access to complete
Unlock access to complete
Funding Insights of OMass Therapeutics
OMass Therapeutics has successfully raised a total of $166.24M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $12.45 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series B — $12.4M
-
First Round
First Round
(01 Jun 2018)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2023 | Amount | Series B - OMass Therapeutics | Valuation | Google Ventures , Sanofi Ventures | |
| Apr, 2022 | Amount | Series B - OMass Therapeutics | Valuation | Google Ventures , Northpond Ventures | |
| Feb, 2020 | Amount | Series A - OMass Therapeutics | Valuation | Syncona , Oxford Science Enterprises |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in OMass Therapeutics
OMass Therapeutics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Syncona, University of Oxford and Oxford University Innovation. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital co-investments are made in UK later-stage businesses.
|
Founded Year | Domain | Location | |
|
Corporate backed venture capital fund investing in multiple sectors
|
Founded Year | Domain | Location | |
|
Life-Sciences focused Early stage Corporate VC Firm investing in the US
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by OMass Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - OMass Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Omass Therapeutics Comparisons
Competitors of OMass Therapeutics
OMass Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Aclaris Therapeutics, Neurocrine and ADMA Biologics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Novel dermatologic therapies are developed for skin conditions.
|
|
| domain | founded_year | HQ Location |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| domain | founded_year | HQ Location |
Plasma-based biologics are developed for immune deficiency and infectious diseases.
|
|
| domain | founded_year | HQ Location |
Small molecule drugs for rare diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Omass Therapeutics
Frequently Asked Questions about OMass Therapeutics
When was OMass Therapeutics founded?
OMass Therapeutics was founded in 2016 and raised its 1st funding round 2 years after it was founded.
Where is OMass Therapeutics located?
OMass Therapeutics is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Is OMass Therapeutics a funded company?
OMass Therapeutics is a funded company, having raised a total of $166.24M across 4 funding rounds to date. The company's 1st funding round was a Series A of $35.87M, raised on Jun 01, 2018.
How many employees does OMass Therapeutics have?
As of Sep 30, 2021, the latest employee count at OMass Therapeutics is 36.
What is the annual revenue of OMass Therapeutics?
Annual revenue of OMass Therapeutics is $54.27K as on Dec 31, 2019.
What does OMass Therapeutics do?
OMass Therapeutics was founded in 2016 in Oxford, United Kingdom, within the biotechnology sector. Proprietary technologies based on mass spectrometry are utilized to examine protein assemblies, enabling detection of drug leads that bind to target complexes via non-covalent interactions and modulate complex formation for therapeutic effects. The pipeline encompasses MC2 for rare endocrine disorders, GPR65 for inflammatory bowel disease, Gasdermin D inhibitors for immunology, and KCC2 for epilepsy.
Who are the top competitors of OMass Therapeutics?
OMass Therapeutics's top competitors include Jazz Pharmaceuticals, ADMA Biologics and PTC Therapeutics.
What products or services does OMass Therapeutics offer?
OMass Therapeutics offers Biochemistry Services and Mass Spectrometry Solutions.
Who are OMass Therapeutics's investors?
OMass Therapeutics has 8 investors. Key investors include Syncona, University of Oxford, Oxford University Innovation, British Patient Capital, and Google Ventures.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.